Colin Kealey

Los Angeles, California, United States
Dr. Kealey has served as NeuroSigma’s Vice President of Medical Affairs since 2016. He spearheaded preparation of materials submitted to the FDA that led to de novo 510(k) clearance of the Monarch eTNS System for treating pediatric ADHD and currently oversees introduction of the Monarch eTNS System to major centers in the EU and the United States. In this role he interfaced with key opinion leaders in the field to convey the science behind eTNS and how it may fit into their current clinical practice. Dr. Kealey also served as Co-Principal Investigator on two of NeuroSigma’s National Institutes of Health (NIH) grants. Prior to joining NeuroSigma, Dr. Kealey was a resident physician in the UCLA Department of Surgery from 2007 to 2011. During his time at UCLA, Dr. Kealey was responsible for all aspects of the care of surgical patients, ranging from outpatient procedures to critically ill patients in the intensive care unit. From 2009 to 2011, Dr. Kealey also served as a Post-Doctoral Researcher at the UCLA Center for Advanced Surgical and Interventional Technology, where he performed pre-clinical research and development on novel medical devices.
Speaking In
[Available On-Demand]
NeuroSigma is commercializing external Trigeminal Nerve Stimulation (eTNS) technology for…